Is Hikma Pharmaceuticals PLC (HKMPF) a Buy, Sell, or Hold?
OTC : HKMPF
Hikma Pharmaceuticals PLC — News
$20.37 USD
-$0.89 (-4.19%)
- Volume
- 40
- Average Volume
- 196
- Market Capitalization
- $4.29B
- P/E Ratio
- 0.19
- Dividend Yield
- 4.01%
- Price Target
- Year High
- $27.96
- Year Low
- $16.34
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.45
- Current Ratio
- $1.82
| Source | Headline |
|---|---|
|
Citi starts Hikma at 'buy' with strategy reset offering compelling entry point
Citi has initiated coverage of Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) with a 'buy' rating and a £17 price target, arguing the generic drugmaker's current valuation offers a compelling entry point. The 12-month target, based on a sum-of-the-parts valuation, implies a share price return of around 14%. proactiveinvestors.co.uk - 2026-07-16 07:21:56 |
|
London BTC's Black Star project hits 16g/t gold as Nevada portfolio grows to four
London BTC Company Ltd (LSE:BTC, OTCQB:VINZF) chairman David Lenigas joined Proactive's Stephen Gunnion to discuss the Black Star gold project and the... proactiveinvestors.com - 2026-07-16 06:30:00 |
|
AtaiBeckley to be acquired by Lilly in deal valued at up to $3.8 billion
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has agreed to be acquired by Eli Lilly and Co (NYSE:LLY) in a transaction valued at up to approximately $3.8... proactiveinvestors.com - 2026-07-16 04:41:00 |
|
Medicus Pharma advances Teverelix Phase 2 study after FDA feedback, IRB approval
Medicus Pharma (NASDAQ:MDCX) said it has received US FDA feedback and central Institutional Review Board approval for its optimized Phase 2 study of... proactiveinvestors.com - 2026-07-16 04:37:00 |
|
Hikma Pharmaceuticals PLC (HKMPY) Sales/ Trading Statement Call Transcript
Hikma Pharmaceuticals PLC (HKMPY) Sales/ Trading Statement Call Transcript seekingalpha.com - 2026-04-23 06:51:32 |
|
UK's Hikma Pharmaceuticals reiterates 2026 outlook despite higher costs from Iran war
Hikma Pharmaceuticals reiterated its 2026 guidance on Thursday, adding that, while it has faced some pressure on shipping, energy, and insurance costs due to the war in the Middle East, a key market for the firm, it was confident it could absorb the higher costs. reuters.com - 2026-04-23 02:27:19 |
